Fimasartan, a novel angiotensin II receptor antagonist

被引：48

作者：

Kim, Je Hak ^{[1
]}

Lee, Joo Han ^{[1
]}

Paik, Soo Heui ^{[1
]}

Kim, Ji Han ^{[1
]}

Chi, Yong Ha ^{[1
]}

机构：

[1] Boryung Pharmaceut Co Ltd, Cent Res Inst, Ansan 425839, Gyonggi Do, South Korea

来源：

ARCHIVES OF PHARMACAL RESEARCH | 2012年 / 35卷 / 07期

关键词：

KOREAN PATIENTS; DOUBLE-BLIND; TOLERABILITY; HYPERTENSION; EFFICACY;

D O I：

10.1007/s12272-012-0700-z

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Fimasartan (KanarbA (R)), an angiotensin II receptor antagonist with selectivity for the AT1 receptor subtype, is a pyrimidinone-related heterocyclic compound that was developed by Boryung Pharm. Co., Ltd. Among numerous synthetic derivatives, fimasartan was chosen as a new drug candidate through in vitro and in vivo screening studies. Pharmadynamic-pharmacokinetic properties and safety profiles were determined in a series of nonclinical and clinical studies. Fimasartan is a new angiotensin receptor blocker, and the first new molecular entity acting on cardiovascular system approved by Korean Food and Drug Administration for the treatment of essential hypertension in September 2010. Further development process for combination therapy and overseas registration is currently ongoing.

引用

页码：1123 / 1126

页数：4

共 9 条

[1]

Antonaccio M J, 1987, Prog Drug Res, V31, P161

[2] Angiotensin II type 1 receptor blockers [J].

Burnier, M .

CIRCULATION, 2001, 103 (06) :904-912

[3] Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Fimasartan Following Single and Repeated Oral Administration in the Fasted and Fed States in Healthy Subjects [J].

Chi, Yong Ha ;

Lee, Howard ;

Paik, Soo Heui ;

Lee, Joo Han ;

Yoo, Byoung Wook ;

Kim, Ji Han ;

Tan, Hyun Kwang ;

Kim, Sang Lin .

AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2011, 11 (05) :335-346

[4] Synthesis and antihypertensive activity of pyrimidin-4(3H)-one derivatives as losartan analogue for new angiotensin II receptor type 1 (AT1) antagonists [J].

Kim, Tae Woo ;

Yoo, Byoung Wook ;

Lee, Joon Kwang ;

Kim, Ji Han ;

Lee, Kyung-Tae ;

Chi, Yong Ha ;

Lee, Jae Yeol .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (04) :1649-1654

[5]

KNHNES, 2011, 1 YEAR REP 5 KOR NAT

[6] Efficacy and Tolerability of Once-Daily Oral Fimasartan 20 to 240 mg/d in Korean Patients with Hypertension: Findings from Two Phase II, Randomized, Double-Blind, Placebo-Controlled Studies [J].

Lee, Howard ;

Yang, Han-Mo ;

Lee, Hae-Young ;

Kim, Jae-Joong ;

Choi, Dong-Ju ;

Seung, Ki-Bae ;

Jeon, Eun-Seok ;

Ha, Jong-Won ;

Rim, Se-Joong ;

Park, Jeong Bae ;

Shin, Joon-Han ;

Oh, Byung-Hee .

CLINICAL THERAPEUTICS, 2012, 34 (06) :1273-1289

[7] Efficacy and Tolerability of Fimasartan, a New Angiotensin Receptor Blocker, Compared With Losartan (50/100 mg): A 12-Week, Phase III, Multicenter, Prospective, Randomized, Double-Blind, Parallel-Group, Dose Escalation Clinical Trial With an Optional 12-Week Extension Phase in Adult Korean Patients With Mild-to-Moderate Hypertension [J].

Lee, Sang Eun ;

Kim, Yong-Jin ;

Lee, Hae-Young ;

Yang, Han-Mo ;

Park, Chang-Gyu ;

Kim, Jae-Joong ;

Kim, Soon-Kil ;

Rhee, Moo-Yong ;

Oh, Byung-Hee .

CLINICAL THERAPEUTICS, 2012, 34 (03) :552-568

[8] New treatment options in the management of hypertension: appraising the potential role of azilsartan medoxomil [J].

Volpe, Massimo ;

Savoia, Carmine .

INTEGRATED BLOOD PRESSURE CONTROL, 2012, 5 :19-25

[9] ANGIO-EDEMA AND URTICARIA ASSOCIATED WITH ANGIOTENSIN CONVERTING ENZYME-INHIBITORS [J].

WOOD, SM ;

MANN, RD ;

RAWLINS, MD .

BRITISH MEDICAL JOURNAL, 1987, 294 (6564) :91-92

← 1 →